These findings provide insight into the molecular mechanism of respiratory failure in SMA and identify ZPR1 and HoxA5 as potential therapeutic targets for developing therapies to reduce the burden of respiratory distress in SMA. Here, HOXA5 is linked to proximal spinal muscular atrophy.